June 30, 2023
AstraZeneca has supported a new podcast that calls for accelerated access to innovative precision medicines and genomic profiling.The podcast is the third in the Private Cancer Physicians of Australia’s (PCPA’s) Cancer Patient Management series.
PCPA, Australia’s peak body for private cancer specialists, has joined other oncology and patient groups to advocate for removing the cost and regulatory barriers for patients with cancer accessing upfront molecular profiling.
pharma in focus 19 June – 23 June 2023
Posted 21 June 2023
Pharma has a key role to play in helping cancer specialists meet their professional development requirements – and a new digital platform could help that partnership grow further.
The Private Cancer Physicians of Australia (PCPA) has announced the launch of a new digital platform, CPD4MedProfessional.com, which will help cancer specialists meet their updated continuing professional development (CPD) requirements.
The new online support program has been developed with the PCPA’s education partners ScienceToLife.
Currently seven pharma companies are part of the PCPA Strategic Alliance Partnership program, supporting educational activities that help medical and radiation oncologists and haematologists meet their continuing professional development (CPD) requirements.
pharma in focus 13 June – 16 June 2023
Posted 15 June 2023
Antibody-drug conjugates (ADCs), described as “biological missiles” and “smart bombs” against cancer, could have the potential to replace chemotherapy for metastatic breast cancer.
Speaking on the Private Cancer Physicians of Australia Podcast series, University of California San Francisco Director of Breast Oncology Professor Hope Rugo said the precise and potent surface-antibody drugs were proving effective and better tolerated than existing treatments.
“This is such an exciting topic for all of us,” Rugo said. “It pervades everything we are discussing now in terms of treatment and clinical practice and research.”
She said ADCs, which contain a cancer-specific monoclonal antibody covalently attached to a cytotoxic drug through a chemical linker, were providing effective in different breast cancer subtypes.
Health Industry Hub 26 May 2023
Pharma News: In an event that showcased the cutting-edge advancements in cancer treatment, the Private Cancer Physicians of Australia (PCPA) joined forces with GenesisCare, their Strategic Alliance Partner, to successfully launch the inaugural PCPA Live Multidisciplinary Teams (MDT) Masterclass. This event witnessed healthcare leaders from Gilead Australia immerse themselves in the daily life of breast cancer patients undergoing complex treatments, providing a unique opportunity to gain invaluable insights into the challenges faced by patients and their MDT teams.
Under the esteemed guidance of PCPA Board member and renowned GenesisCare Medical Oncologist, Professor Stephen Clarke, alongside esteemed colleagues Dr Katrina Moore and Dr Sally Baron-Hay, more than 15 industry leaders in cancer care came together at the North Shore Campus in Sydney. This facility, which encompasses both GenesisCare and the prestigious Royal North Shore Hospital, served as the perfect setting for the interactive Masterclass.
pharma in focus 26th May 2023
Gilead leaders attended a newly launched Multidisciplinary Teams (MDT) Masterclass in cancer treatment this week hailed as an “immersive experience” to help deliver better outcomes for breast cancer patients.
The two-day interactive masterclass is an initiative of the peak body for private cancer clinicians, Private Cancer Physicians of Australia (PCPA) and its strategic alliance partner, GenesisCare.
It was held at the North Shore Campus in Sydney, which incorporates GenesisCare and Royal North Shore Hospital.
Bio Pharma Dispatch 25 May 2023
The inaugural PCPA Live Multidisciplinary Teams (MDT) Masterclass in cancer treatment was launched this week by the peak body for private cancer clinicians and its strategic partner
Under the leadership of PCPA Board member and leading GenesisCare Medical Oncologist, Professor Stephen Clarke and his colleagues, participants from Gilead experienced, first-hand, what a day in the life of a breast cancer patient, undergoing complex treatment, really entails for them and their MDT teams.
pharma in focus 4th May 2023.
Big names are readying to debate “the true value of oncology” at the Private Cancer Physicians of Australia’s (PCPA) 2023 conference over the weekend in Melbourne – just days ahead of the 2023-24 Federal Budget.
The ‘Embracing the Challenge: Advancing Cancer Care’ conference will be held at the InterContinental hotel, The Rialto, and is sponsored by a range of pharma’s including Diamond Sponsor Roche and Gold Sponsors Gilead, Kite, and Servier.
BioPharmaDispath 27 Feb 2023.
Australia’s peak body of private cancer specialists has partnered with companies to launch a suite of interactive education and engagement platforms with the aim of enhancing the cancer care journey for patients.
The president of the Private Cancer Physicians of Australia (PCPA), Associate Professor Christopher Steer, said prioritising the needs of Australians with cancer, and those who care for them, was the driving force behind the organisation’s inaugural ‘Strategic Alliance Partnership’ program.
Pharma in Focus 28 Feb 2023.
The Private Cancer Physicians of Australia (PCPA) has kicked off its Strategic Alliance Partnership program with a podcast supported by Servier.
Outgoing CEO of Servier Australia, Brad Lloyd, said the company was proud to be a founding Strategic Partner with the PCPA, which aims to advance the cancer care journey of Australians, particularly through the private system. “We’re committed to improving the lives of all Australian cancer patients today and working together to develop better treatments for tomorrow,” Lloyd said.